Two Sigma Investments LP Acquires 6,993 Shares of Mural Oncology plc (NASDAQ:MURA)

Two Sigma Investments LP grew its holdings in shares of Mural Oncology plc (NASDAQ:MURA) by 12.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 65,150 shares of the company’s stock after purchasing an additional 6,993 shares during the period. Two Sigma Investments LP owned about 0.38% of Mural Oncology worth $210,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in MURA. Virtu Financial LLC bought a new stake in shares of Mural Oncology in the fourth quarter valued at approximately $129,000. Renaissance Technologies LLC lifted its position in shares of Mural Oncology by 17.4% during the 4th quarter. Renaissance Technologies LLC now owns 238,465 shares of the company’s stock valued at $768,000 after acquiring an additional 35,403 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Mural Oncology during the 4th quarter valued at $181,000. Northern Trust Corp grew its holdings in shares of Mural Oncology by 22.0% during the 4th quarter. Northern Trust Corp now owns 39,966 shares of the company’s stock worth $129,000 after purchasing an additional 7,197 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Mural Oncology in the fourth quarter worth $68,000. 80.21% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on MURA shares. Raymond James cut shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 price objective for the company. in a research report on Tuesday, March 25th. Morgan Stanley lowered shares of Mural Oncology from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, March 25th. Jones Trading restated a “hold” rating on shares of Mural Oncology in a research report on Tuesday, March 25th. Finally, HC Wainwright cut their target price on Mural Oncology from $18.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, March 26th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $13.00.

Mural Oncology Trading Down 1.2%

MURA stock opened at $2.53 on Friday. The firm has a 50-day moving average price of $2.41 and a 200-day moving average price of $3.14. Mural Oncology plc has a 12 month low of $0.95 and a 12 month high of $4.74. The stock has a market capitalization of $43.69 million, a P/E ratio of -0.28 and a beta of 3.36.

Mural Oncology (NASDAQ:MURA) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.93) EPS for the quarter, beating the consensus estimate of ($2.12) by $0.19. As a group, equities analysts predict that Mural Oncology plc will post -7.54 EPS for the current fiscal year.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.